EUCTR2014-005614-29-FR进行中（未招募）不适用
A Phase 2 multicenter, randomized, placebo controlled, double-blind study to assess the safety and efficacy of CC-486 (oral azacitidine) in combination with pembrolizumab (MK-3475) versus pembrolizumab plus placebo in subjects with previously treated locally advanced or metastatic non-small cell lung cancer
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 90
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •-Subject is = 18 years of age at the time of signing the informed consent form.
- •-Subject has histologically or cytologically confirmed squamous or non-squamous NSCLC.
- •-Subject has stage IIIB or IV NSCLC and was pretreated with 1 prior systemic platinum based chemotherapy.
- •-Subject has provided a formalin fixed tumor tissue sample from a biopsy of a tumor lesion either at the time of or after the diagnosis of metastatic disease has been made AND from a site not previously irradiated to assess for PD-L1 status.
- •-Subject has radiographically-documented measurable disease, as per RECIST 1.1.
- •-Subject has an ECOG performance status of 0 to 1.
- •-Subject has adequate organ and bone marrow functions
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 30
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 60
排除标准
- •-Subject has known sensitizing EGFR and/or positive ALK mutation
- •-Subject has received prior therapy with any other anti-PD-1, or PD-L1 or PD-L2 agent or an antibody targeting other immuno-regulatory receptors or mechanism
- •-Subject has had radiotherapy = 4 weeks or limited field radiation for palliation = 2 weeks prior to starting IP, and/or from whom = 30% of the bone marrow was irradiated.
- •-Subject has received a live-virus vaccination within 30 days of planned treatment start. Seasonal flu vaccines that do not contain live virus are permitted
- •-Subject has active autoimmune disease that has required systemic treatment within the past 2 years
- •-Subject with uncontrolled or symptomatic central nervous system (CNS) metastases and/or carcinomatous meningitis
研究者
相似试验
已完成
不适用
A multicenter, randomized, double-blinded, placebo controlled, superiority, medical device pivotal clinical trial to evaluate the safety and efficacy of vibrator of medical device BAMK-M100 (D) to improve constipation in patients with chronic functional constipatioKCT0006711BMS140
进行中（未招募）
不适用
A one-year multi-center study, to evaluate safety and efficacy of zoledronic acid given every six months compared to placebo in children with weakened bone treated with long-term steroidsEUCTR2008-001252-52-PLovartis Pharma Services AG92
进行中（未招募）
1 期
A multicenter, randomized, double-blind, placebo controlled phase III study of panobinostat in combination with bortezomib and dexamethasone in patients with relapsed multiple myeloma.Multiple Myeloma (MM), relapsed or relapsed-and-refractoryMedDRA version: 16.1Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864EUCTR2009-015507-52-DKovartis Pharma Services AG762
进行中（未招募）
1 期
A clinical study investigating the efficacy, tolerability, and safety of two dosing regimens of continuous subcutaneous ND0612 infusion given as adjunct treatment to oral levodopa in patients with Parkinson’s disease with motor fluctuationsSubjects with Parkinson’s Disease with motor fluctuationsMedDRA version: 20.0 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disordersEUCTR2016-002033-30-GBeuroDerm Ltd.240
进行中（未招募）
1 期
A clinical study investigating the efficacy, tolerability, and safety of continuous subcutaneous ND0612 infusion given as adjunct treatment to oral levodopa in patients with Parkinson’s disease with motor fluctuationsSubjects with Parkinson’s Disease with motor fluctuationsMedDRA version: 19.1 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disordersEUCTR2016-002033-30-FReuroDerm Ltd.150